1. Home
  2. MNMD vs NNNN Comparison

MNMD vs NNNN Comparison

Compare MNMD & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mind Medicine (MindMed) Inc.

MNMD

Mind Medicine (MindMed) Inc.

HOLD

Current Price

$14.72

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

N/A

Current Price

$32.99

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MNMD
NNNN
Founded
2019
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
MNMD
NNNN
Price
$14.72
$32.99
Analyst Decision
Strong Buy
Analyst Count
9
0
Target Price
$30.33
N/A
AVG Volume (30 Days)
2.0M
33.4K
Earning Date
11-06-2025
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.06
Revenue
N/A
$6,920,153.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$584.00
Revenue Growth
N/A
N/A
52 Week Low
$4.70
$5.18
52 Week High
$14.81
$55.65

Technical Indicators

Market Signals
Indicator
MNMD
NNNN
Relative Strength Index (RSI) 67.62 53.52
Support Level $13.06 $27.32
Resistance Level $14.81 $35.45
Average True Range (ATR) 0.84 3.97
MACD 0.11 -0.10
Stochastic Oscillator 82.03 53.09

Price Performance

Historical Comparison
MNMD
NNNN

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Share on Social Networks: